91 results about "Lipid particle" patented technology

The instant disclosure relates to lipid particles that harbor cationic lipids, the particles found to be capable of delivering associated cargoes - particularly nucleic acid cargoes when formulated as nucleic acid-lipid particles - intracellularly to skin tissue cells when administered topically to a subject. The instant disclosure provides compositions comprising such lipid particles, optionally in association with a therapeutic agent (e.g., a therapeutic mRNA and / or nucleic acid controller system), as well as methods and kits for delivering a lipid particle-associated therapeutic agent and / or for treating or preventing a disease or disorder, e.g., a skin disease or disorder, in a subject, using one or more lipid particle compositions provided herein.

The present disclosure relates to a hydrogel ink comprising a lipid particle, a polynucleotide supported within the lipid particle, and a bio-ink. In one embodiment, the lipid particles comprise extracellular vesicles. The disclosure also relates to hydrogels thereof and their use in treating neurological diseases or conditions or regenerating soft tissue.

The invention relates to a QS-21 loaded nano adjuvant as well as a preparation method and application thereof. According to the nano adjuvant, the biodegradable polymer, cholesterol and cationic lipid entrapped QS-21 are utilized to form solid lipid particles in an O / W mode, the solid lipid particles have good dispersity, the surfaces of the solid lipid particles are positively charged, and the solid lipid particles can adsorb negatively charged antigen protein to prepare a nano adjuvant vaccine. The cholesterol in the nano adjuvant vaccine can be combined with the QS-21, so that entrapment of the QS-21 can be better realized, the safety and the stability of the nano adjuvant vaccine are improved, and the nano adjuvant vaccine has a wide application prospect in prevention of virus infection.

The present invention relates to compositions comprising nucleic acid-lipid particles, wherein the nucleic acid-lipid particles are characterized by encapsulation of the nucleic acid in a lipid bilayer. The present invention further relates to said compositions for use in preventing and / or treating disease, particularly for use in preventing and / or treating cancer. The present invention further relates to methods for producing compositions comprising said nucleic acid-lipid particles.

Disclosed herein are compositions for use in a variety of agricultural methods, the compositions comprising a plurality of naturally derived lipid particles comprising a phospholipid, a non-polar lipid, and a surface modifier, and further comprising a biologically active substance.

The present disclosure relates to a novel drug delivery system, which comprises a lipid particle and a modified red blood cell. The present disclosure also relates to preparation of the drug delivery system and therapeutic use thereof.

The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.

The present disclosure provides lipid nanoparticles that are beneficially effective in the targeting of hepatic stellate cells with enhanced specificity. The lipid nanoparticles include five lipid components, including a permanently charged cationic lipid that is a quaternary ammonium lipid. The disclosure also provides pharmaceutical compositions and methods including the provided lipid nanoparticles.

The invention discloses nucleotide of fusion protein for coding neutrophil elastase and application of the nucleotide. A nucleotide sequence for coding the fusion protein is as shown in SEQ ID NO. 8; the nucleotide sequence of mRNA (messenger ribonucleic acid) for coding the fusion protein is as shown in SEQ ID NO. 12; the fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment. The mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the wild type ELANE can achieve a tumor elimination effect only by complex intratumor injection. According to the mRNA preparation which is encapsulated by the nano-lipid particles and is used for coding the ELANE fusion protein, tumor elimination in a mouse body can be realized only through intramuscular injection administration, the operation is simpler and more convenient, and the mRNA preparation is beneficial to treatment of scattered and tiny tumor focuses in the body.

This invention belongs to the field of nanocarrier and immunotherapy technology, specifically relating to a lipid nanoparticle targeting tumor-associated macrophages, a combined delivery method, and its application in tumor immunotherapy. The lipid nanoparticles targeting CD206 tumor-associated macrophages constructed in this invention are used for efficient in vivo delivery of multifunctional nucleic acid molecules, achieving immune regulation, gene editing, and anti-tumor therapy. This invention achieves targeted delivery and multifunctional synergistic effects through lipid particle design, nucleic acid sequence design, and in vitro and in vivo functional verification. Through in vivo delivery of ipLNPs, macrophages can simultaneously achieve: 1) expression of anti-PD-L1 antibodies, blocking immunosuppressive signals; 2) expression of HER2-CAR structures, enhancing phagocytosis and killing ability against tumors; and 3) remodeling of the tumor immune microenvironment through CRISPR / Cas9-mediated FN1 knockout. The lipid nanoparticles constructed using this invention can solve the problem of insufficient targeting of immune cells in the tumor microenvironment by traditional LNP delivery systems.

The problem to be solved by the present invention is to provide cationic lipids for oligonucleotide delivery which can provide a high drug: lipid ratio, which protect the nucleic acid from degradation and clearance in serum, which are suitable for systemic delivery, which can result in intracellular delivery of the nucleic acid, and which are well tolerated, provide an adequate therapeutic index, and treatment of patients with an effective dose of the nucleic acid is not associated with significant toxicity and / or risk to the patient.SOLUTION: The present invention relates to cationic lipids having one or more biodegradable groups located in the lipid portion (e.g., hydrophobic chain) of the cationic lipid. These cationic lipids can be incorporated into lipid particles for the delivery of active agents such as nucleic acids. The present invention also relates to a lipid particle comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the invention and optionally a sterol. The lipid particles may further comprise a therapeutic agent, such as a nucleic acid.SELECTED DRAWING: None

To provide a composition for cosmetic including ceramide-containing lipid particles which is excellent in dispersion stability and use feeling.SOLUTION: A composition for cosmetic including ceramide-containing lipid particles which contains phospholipid, cholesterol, lysophospholipid and ceramide, has a volume average particle diameter of 10nm or more and 600nm or less, and polydispersity of 0.50 or less.SELECTED DRAWING: None

According to one embodiment, a substance delivery carrier and a composition are used for delivering an intended substance to a myeloid tumor cell. The substance delivery carrier has a lipid particle, and an intended substance encapsulated in the lipid particle. The lipid particle contains, as a constituent thereof, at least a first lipid represented by formula (I).

Embodiments of the present disclosure generally relate to a new class of compositions that include VZV IE62 or a derivative thereof (e.g., a mutant) and lipid particles. Embodiments of the present disclosure also relate to uses of the compositions for treating, alleviating, or reducing the severity of, various diseases or medical conditions in a patient. For example, embodiments described herein may be utilized for treating, alleviating, or reducing the severity of various neuroinflammation and related pathologies and diseases such as psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, neuromyelitis optica, or dementia, among others.

Disclosed are compositions comprising lipid particles and self-replicating RNA molecules and methods of treatment with the compositions.

The present disclosure provides RNA-lipid particles and formulations comprising novel lipids and therapeutic agents, methods of making RNA-lipid particles, and methods of delivering and / or administering RNA-lipid particles. In particular, the present disclosure provides RNA-lipid particles comprising a polyomithine-based lipid conjugate or conjugate of polyomithine and a lipid-like material, and RNA (e.g., single-stranded messenger RNA encoding a peptide or protein of interest), and methods of making RNA-lipid particles. Particles comprising mRNA and polyomithine are delivered to target tissues following administration via intramuscular, intravenous, or subcutaneous routes.

To provide: a topical composition which effectively improve the skin barrier function by enhancing the skin's own ability to maintain and / or repair the strength of its barrier, so that the protective barrier formed is completely natural; and a skin composition which exhibits enhanced skin protection properties and enhanced skin moisturization.SOLUTION: The presently claimed invention relates to liquid crystal lipid particles. The presently claimed invention relates to liquid crystal lipid particles which are used in a topical composition which has high moisturization efficacy, excellent skin feel, skin softness and skin smoothness benefits. The liquid crystal lipid particles are effective in improving the barrier function and protecting the skin from harmful pollutants, and also enhance the skin moisturizing effect.SELECTED DRAWING: None

The application belongs to the technical field of biological medicine, and particularly relates to a kind of nano-lipid granules for treating atherosclerosis and its preparation method and application, the nano-lipid granules take PLGA encapsulated PDHA1 protein and aggregation-induced emission molecule as core, foam cell membrane is coated on the surface of PLGA, the outermost layer is coated with active oxygen responsive liposome;Aggregation-induced emission molecule is the coupling product of diphenylamine donor unit and benzothiadiazole-thiophene acceptor unit.The present application co-delivers PDHA1 protein and AIE photothermal molecule, homologous targeting of foam cell membrane, active oxygen responsive liposome outer layer and near-infrared two-zone imaging / photothermal therapy function is integrated in a single nano platform, realizes the precise diagnosis of HHcy-AS, metabolic microenvironment repair and photothermal removal of foam cells multimodal synergistic therapy, and provides a new treatment strategy for atherosclerosis, especially high homocysteine related atherosclerosis.

To provide a lipid particle for nucleic acid delivery and its clinical application.SOLUTION: A lipid particle comprising a cationic lipid encapsulating a nucleic acid sequence encoding a protein of at least 500 amino acids in length, wherein: Wherein m is 0 or 1, A1 and A2 are each independently a saturated or unsaturated linear unbranched alkylene chain of at least 8 carbons in length, L1 is a first linking group that is an alkylene of 1-4 carbons in length, X is - O-C (= O) - or - NH-C (= O) -, L2 is a second linking group that is an alkylene of 1-4 carbons in length, R1 and R2 are each independently hydrogen, alkyl or cycloalkyl, or R1 and R2 together with the nitrogens to which they are attached form a heteroalicyclic ring, provided that when X is - O-C (= O) -, m is 1. The lipid particle according to claim 1.SELECTED DRAWING: Figure 1-1

Disclosed herein are compositions including a plurality of nature-derived lipid particles (NLPs) comprising phospholipids, essential oils, blends of essential oils and polar lipids, and optionally surface modifiers, and further comprising bioactives, wherein the NLPs comprise a hydrophobic core, for use in a variety of agricultural methods.

Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and / or treating infection with human papillomavirus type 6 and / or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof.[In the formula, R1, R2, p, L1 and L2 are as defined in the specification.]

The invention relates to the technical field of blood analysis, in particular to a scatter diagram-based lipid particle identification method and a blood cell analyzer. The method comprises the following steps: extracting lipid particle characteristics in a three-dimensional scatter diagram of a blood sample to obtain sample curve characteristics and particle number characteristics, and obtaining a lipid particle identification result of the three-dimensional scatter diagram based on the sample curve characteristics and the particle number characteristics; and outputting alarm information under the condition that the lipid particle recognition result represents that the lipid particles exist in the three-dimensional scatter diagram. By adopting the method, the cell counting accuracy can be improved.

An object of the present invention is to provide a lipid particle that can be produced without using a PEG-modified lipid, or that exhibits higher drug effects, safety, or stability than those of a lipid particle produced using a PEG-modified lipid; or that has immunokinetics different from those of a lipid particle produced using a PEG-modified lipid.A lipid particle comprising an ionized lipid, a phospholipid, and a sterol as lipid components of the lipid particle, and a modified polysaccharide containing a hydrophobic group.

The present invention addresses the problem of providing: a compound or a salt thereof which constitutes lipid particles that make it possible to achieve a high nucleic acid encapsulation rate and excellent nucleic acid delivery; and lipid particles and a pharmaceutical composition which use the same and make it possible to achieve a high nucleic acid encapsulation rate and excellent nucleic acid delivery. The present invention provides a compound represented by formula (1) or a salt thereof. In the formula, the symbols have the meanings as defined in the specification of the present application.

The present invention generally relates to nucleic acid particles, in particular nucleic acid-lipid particles, comprising targeting moieties that are bound to the particles, and to pharmaceutical compositions containing the nucleic acid particles and their uses in medicine.